Sanofi India

Mumbai, India Founded: 1956 • Age: 70 yrs Listed
Manufacturer of pharmaceutical products and vaccines
Request Access
Report Incorrect Data
Page last updated

About Sanofi India

Sanofi India is a publicly listed company based in Mumbai (India) founded in 1956. The company has 991 employees. Its Indian entity Sanofi India Limited reported revenue of ₹2,916 Cr. Sanofi India offers products and services including Vaccines and Diabetes Solutions. Its focus areas include Traditional Pharmaceuticals, Traditional Nutraceuticals, Diversified and Herbal.

Company details

Manufacturer of pharmaceutical products and vaccines. It produces a variety of dosage forms including tablets, capsules, eyeear drops, and injectables. These products are manufactured to stringent global quality guidelines and are approved by various international regulatory agencies. The company also manufactures products for domestic consumption and export. Its therapeutic areas include diabetes, cardiology, thrombosis, central nervous system disorders, and anti-histamines. The company utilizes both its own manufacturing facilities and third-party manufacturers.

  • Headquarters Mumbai, India
  • Employees 991
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website sanofiindialtd.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Sanofi India Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹6,511 Cr

    SANOFI · NSE

  • Share Price
    ₹2,831.10

    +0.13% today

  • Revenue
    ₹2,013 Cr

    Dec 2024 · +0.9% YoY

  • EBITDA
    ₹453 Cr

    Margin 22.5%

  • Net Profit
    ₹442 Cr

    Dec 2024 · -24.9% YoY

  • P/E (TTM)
    21.0x

    P/B 9.3x

  • ROE
    47.1%

    ROCE 48.0%

  • Debt / Equity
    0.02

    Interest cover 0.4x

  • Employee Count
    991

Products & Services of Sanofi India

Sanofi India offers a comprehensive portfolio of products and services, including Vaccines and Diabetes Solutions.

Vaccines
Pharmaceutical Products

Vaccines are developed and manufactured for disease prevention and are distributed both domestically and internationally.

Diabetes Solutions
Medicines

Medicines for diabetes management are provided as part of the therapy areas addressed by Sanofi.

Apps and channels of Sanofi India

its YouTube channel Sanofi has 33K subscribers and 30 videos.

Sanofi
YouTube 33K subscribers 30 videos Science & Technology
Open channel

Videos from Sanofi India

The most watched videos on Sanofi India's YouTube channel, Sanofi (33K subscribers). Click a video to play it here.

Sanofi – Second Quarter 2025
801 views
Sanofi – VivaTech 2025 Wrap-Up
622 views
Sanofi – Understanding Atopic Dermatitis
410 views
Sanofi – VivaTech 2025 Jour 4: L’IA transforme le parcours santé
404 views

More on Sanofi.

Board of directors of Sanofi India Limited (Sanofi India)

Sanofi India Limited is the primary company behind Sanofi India. The board of Sanofi India Limited currently have 9 directors; the longest-serving is Rahul Bhatnagar, appointed in 2020. 45 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rahul Bhatnagar
DIN 07268064
Director29 Jul 20206 yrs 2 moSanofi India Limited
Vaibhav Vinayak Karandikar
DIN 09049375
Director23 Feb 20215 yrs 7 moSanofi India Limited
Rachid Ayari
DIN 10408699
Whole-time director01 Dec 20232 yrs 10 moSanofi India Limited
Eric Yves Mansion
DIN 10654588
Director03 Jun 20242 yrs 4 moSanofi India Limited
Mahadev Keshav Gawade
DIN 11231316
Whole-time director11 Aug 20251 yr 2 moSanofi India Limited
Deepak Arora
DIN 07495638
Managing Director27 Oct 202511 moSanofi India Limited
Sudipta Chakraborty
DIN 07166912
Whole-Time Director01 Mar 20267 moSanofi India Limited
Siraj Azmat Chaudhry
DIN 00161853
Director01 Apr 20266 moSanofi India Limited
Rajani Kesari
DIN 02384170
Director01 Apr 20266 moSanofi India Limited

People of Sanofi India

637 people are tracked at Sanofi India (367 in leadership, 14 in board & advisors, 256 in team); the tracked headcount is 991.

NameRoleGroup
Rajaram Narayanan
Managing DirectorLeadership
Mikhael Aboukrat
Head Of Service Management & C2rLeadership
Paul Hudson
Chief Executive OfficerLeadership
Edouard Clavel
Finance Business Partner Vaccines FranceLeadership
Kristin Breitschopf
Head Of Immunology & Inflammation Research Program Management, Portfolio Innovation And ExcellenceLeadership
Lavesh Gwalani
Immunology Group Head - Principal Scientist, Gene Therapy ImmunologyLeadership
Bernadette Wang
Senior Director, Head, US Public Affairs And Patient Advocacy, NeurologyLeadership
Jim Tartaglia
VP R&d; Head Of New Vaccine Strategy And ExecutionLeadership
Kei Takada
Head Of RSV Franchise, Vaccines Business UnitLeadership
Marie-Helene Chassagne
Head Of Reward And Performance EMEA And Global Corporate FunctionsLeadership
Dumont Stephanie
Executive Assistant To The Chief Quality OfficerLeadership
Lisa Barbieri Moher
Head Of North America Distribution Package Engineering And GraphicsLeadership
Ina Vannijvel
Digital Transformation, Program Director And Change CoachLeadership
Ivana Silli
Partner Markets Europe & Eurasia Quality Manager At SanofiLeadership
Mathias Ganz
ITS Business PartnerLeadership
Luis Barreto
Vice President, Immunization And Science PolicyLeadership
Uday Sheth
Head Of Digital Gbus Agile & Service ExcellenceLeadership
Dominika Kovacs
General Manager, US Respiratory Franchise Speciality CareLeadership
Bastian Frehse
Country CFOLeadership
Okan Güner
Vaccines Head Of Business Planning EurasiaLeadership

617 more people are available in the full profile.

Premium access

Complete people profiles for Sanofi India

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sanofi India

Sanofi India is a publicly listed company on the NSE with ticker symbol SANOFI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 May 2003
  • Listed onNSE: SANOFI
  • Listed entitySanofi India Limited
  • Exchange sectorHealth technology
  • ISININE058A01010
  • Share price₹2,990.20 (+1.15% on the day) · 2026-10-14
  • Market capitalisation₹6,820 Cr
  • Price to earnings21.3
  • EPS (diluted, trailing year)₹140.60
  • Dividend yield4.19%
  • Volume (last session)7,455

Financials of Sanofi India

Exchange-reported figures of Sanofi India Limited, the listed company behind Sanofi India (NSE: SANOFI).

Financial Highlights

Dec 2024 · Consolidated
Revenue
₹2,013 Cr
+0.9% YoY
EBITDA
₹453 Cr
-7.1% YoY
Profit After Tax
₹442 Cr
-24.9% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsDec 2024Dec 2023
Income statement
Revenue2,0131,996
Revenue growth+0.9%-
EBITDA453488
EBITDA margin+22.5%+24.4%
Profit before tax531767
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
Balance sheet
Cash flow
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
MetricsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income statement
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Profit before tax4455318468641,258677600
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Balance sheet
Cash flow
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue438472420475406536515524
Revenue growth (YoY)+7.7%-11.9%-18.5%-9.3%-12.3%---
Other income6.204.402.804.908.703.3013.902.30
Total expenses322330330368311364397404
EBITDA11514390.3010794.90172118120
EBITDA margin+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%+22.8%
Depreciation8.909.009.509.109.109.609.609.00
Interest0.300.300.600.400.400.300.400.40
Profit before tax11213883.0010294.10165122113
Tax28.8035.3021.3026.3024.6045.8030.9030.40

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
ParticularsDec 2024Dec 2023
Revenue2,0131,996
Revenue growth+0.9%-
Other income116317
Total expenses1,5601,508
Employee cost240281
EBITDA453488
EBITDA margin+22.5%+24.4%
Depreciation36.7036.50
Interest1.501.70
Profit before tax531767
Tax118164
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
ParticularsDec 2024Dec 2023
Growth
Sales growth+0.9%-
EBITDA growth-7.1%-
PBT growth-30.8%+9997.0%
Net income growth-24.9%-
Profitability & leverage
Net income margin+20.5%+30.2%
Return on capital employed+48.0%+48.1%
Return on net worth+47.1%+58.0%
Debt / equity0.020.02
Long-term debt / equity0.010.01
Interest cover0.360.38
Efficiency & per share
Fixed asset turnover3.653.67
Inventory turnover3.463.01
Debtors turnover11.1315.16
EPS (₹)179.70262.13
Dividend per share (₹)117.00167.00
Book value per share (₹)374.17441.39
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue438472420475406536515524
Revenue growth (YoY)+7.7%-11.9%-18.5%-9.3%-12.3%---
Other income6.204.402.804.908.703.3013.902.30
Total expenses322330330368311364397404
EBITDA11514390.3010794.90172118120
EBITDA margin+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%+22.8%
Depreciation8.909.009.509.109.109.609.609.00
Interest0.300.300.600.400.400.300.400.40
Profit before tax11213883.0010294.10165122113
Tax28.8035.3021.3026.3024.6045.8030.9030.40
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
Other income19.7011683.1020456489.8094.10
Total expenses1,3731,5602,0472,0662,1942,2302,465
Employee cost185240371406434461450
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Depreciation37.3036.7039.6041.9066.7082.2099.90
Interest1.701.501.701.701.801.800.30
Profit before tax4455318468641,258677600
Tax118118243244313200186
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Growth
Sales growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA growth+2.4%-43.6%+14.1%-7.6%+13.6%+10.8%-
PBT growth-16.3%-37.2%-2.1%-31.3%+85.7%+12.9%-1.6%
Net income growth-21.7%-25.1%+12.3%-9.5%+14.3%+12.4%-
Revenue CAGR (3Y)-12.8%-12.0%-0.6%-3.4%+2.2%+5.7%+9.1%
EBITDA CAGR (3Y)-13.0%-15.9%+6.2%+5.1%+6.9%+7.7%+4.2%
Profitability & leverage
Net income margin+17.8%+20.5%+21.2%+22.4%+31.9%+16.5%+13.5%
Return on capital employed+54.2%+48.4%+70.6%+40.3%+33.8%+28.9%+27.8%
Return on net worth+40.6%+47.2%+52.7%+30.1%+26.8%+20.9%+19.4%
Debt / equity0.020.020.020.010.010.000.00
Long-term debt / equity0.020.010.010.010.010.000.00
Interest cover0.400.360.220.260.260.310.06
Efficiency & per share
Fixed asset turnover3.233.655.315.144.233.483.28
Inventory turnover4.533.465.326.927.786.936.45
Debtors turnover9.0411.1321.8620.3720.3315.6016.06
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Dividend per share (₹)123.00117.00167.00570.00490.00365.00349.00
Book value per share (₹)325.74374.17441.52554.70967.65921.301,061.87

Web traffic of Sanofi India

Websites that share an audience with Sanofi India (sanofiindialtd.com).

Similar websites

Websites whose visitors overlap most with Sanofi India. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
sanofi.in
sanofi.in
100%
–
Bliss GVS
blissgvs.com
85%
10.6K#3,528,800View details
wallacepharma.com
wallacepharma.com
85%
#5,627,962–
Ciron
cironpharma.com
85%
2.4K#7,858,699View details
Elder Pharamaceuticals
elderindia.com
84%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 17 similar websites and full traffic analytics for Sanofi India

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 17 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Sanofi India (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sanofi India

Sanofi Healthcare India: Buys 3.5 Million Shares, 15.20% Of Sanofi India From Hoechst GmbH Through Block Deal; No Change In Promoter Group Ownership.
Exchange Update • 16 days ago
Dividend income at risk? 8 stocks with inconsistent dividend payout: Indian Oil, Sanofi India, UTI AMC, and more | Stock Market News
mint • 23 days ago
Sanofi Healthcare buys 15.2% stake in Sanofi India for Rs 1,068 crore - The Economic Times
Economic Times • 29 days ago
Sanofi Healthcare India buys 15.19% stake in Sanofi India - The HinduBusinessLine
Thehindubusinessline • 29 days ago
SANOFI: RS 1068.2CR NSE BLOCK TRADE; FOR ~3500000 SHARES, AT RS 3052 (PRE-OPEN)
Exchange Update • 29 days ago
Stocks in news: Biocon, Bank of Baroda, TCS, Sanofi India and Tata Capital - The Economic Times
Economic Times • 1 month ago
Company can face criminal prosecution even if no individual is made accused: Supreme Court - The Economic Times
Economic Times • 1 month ago
Stocks to Watch for September 9: Bank of Baroda, GE Shipping, Sanofi India and more - CNBC TV18
CNBCTV18 • 1 month ago
Sanofi India's petition to quash criminal proceedings dismissed by Supreme Court - CNBC TV18
CNBCTV18 • 1 month ago
Sanofi India Says Tax Demand Of 7.3 Million Rupees Vacated For AY 2019-20
Reuters • 2 months ago
Premium access

Complete news archive for Sanofi India

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanofi India

Sanofi India was founded in 1956.

Sanofi India is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Sanofi India has 991 employees.

The primary company behind Sanofi India, Sanofi India Limited, reported revenue of ₹2,916 Cr for FY 2023, up 3% year on year.

Manufacturer of pharmaceutical products and vaccines. It produces a variety of dosage forms including tablets, capsules, eyeear drops, and injectables. These products are manufactured to stringent global quality guidelines and are approved by various international regulatory agencies. The company also manufactures products for domestic consumption and export. Its therapeutic areas include diabetes, cardiology, thrombosis, central nervous system disorders, and anti-histamines. The company utilizes both its own manufacturing facilities and third-party manufacturers.

Sanofi India offers Vaccines and Diabetes Solutions.

Yes, Sanofi India is publicly traded on NSE under the ticker symbol SANOFI.

Sanofi India operates through Sanofi India Limited.

The legal entities of Sanofi India currently have 10 directors, including Vaibhav Vinayak Karandikar, Rahul Bhatnagar, Deepak Arora and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available